You and your doctor need to be following this closely because of this.
Parkinson’s Disease May Have Link to Stroke March 2017
I'm doing coffee for prevention. Don't listen to me, I'm not medically trained. Is your doctor?
How coffee protects against Parkinson’s Aug. 2014
Experts Propose Revising the Criteria for Diagnosis of Parkinson’s Disease
In
the past 25 years it has become clear that some symptoms of Parkinson’s
disease (PD) occur decades before the development of motor symptoms and
clinical diagnosis, and that monitoring these emerging symptoms may
provide important insights into the origin and development of the
disease. Understanding this “prodromal” phase, along with the
development of new treatments, may enable earlier treatment to prevent
the disease from developing, according to experts writing in a
supplement to the Journal of Parkinson’s Disease.
“Brilliant work of many in different scientific fields has paved the way for the concept of prodromal PD -- that is, a phase of years to decades in which non-motor and subtle motor symptoms may indicate spreading PD pathology, but do not meet the threshold for diagnosis according to the classic motor-based clinical criteria,” wrote Daniela Berg, MD, Christian-Albrechts-University of Kiel, Kiel, Germany, and colleagues.
The authors define the main anchors of the concept of the prodromal phase as the broadly accepted fact that the neurodegenerative process in PD spreads slowly, possibly starting in the gut or olfactory system and finally encompassing much of the nervous system.
Increasing knowledge of risk factors and clinical symptoms that precede the typical motor manifestations by years to decades and can be correlated to imaging and histopathological findings
The authors have constructed a mathematical model that makes it possible to calculate an individual’s personal risk of being in the prodromal phase of PD. However, there are several limitations to this model, such as the time taken to conversion to PD, age, sex factors, and subtypes with undetectable prodromal stages.
“The prodromal PD criteria are meant to be research criteria and constitute a first step in what should be a continually-updated process,” the authors wrote.
Biomarkers and wearable technology such as mobile phones are expected to play a role in greater accuracy of diagnosis in the prodromal phase. The goal of biomarker research, as well as quantitative motor assessment, is to use new data arising from objective measurements to enable earlier detection of the neurodegenerative process and possibly motor symptoms. It would also facilitate the development of neuroprotective trials in early stages.
Some key questions that the authors hope to see resolved are: When is the starting point of PD? What will define the disease? Will it still be motor symptoms (possibly typical subtle ones), or will it be biomarker evidence of nigrostriatal system neurodegeneration without motor symptoms? Will it be a certain combination of non-motor signs? Or will it be based upon non-clinical biomarkers, similar to changes in Alzheimer’s disease?
By 2040, the authors hope that prodromal criteria will be incorporated into active neuroprotective treatment programs, allowing a program of population-based screening followed by early treatment and ultimately the prevention of clinical PD from ever becoming manifest.
“Our review highlights the importance of making an earlier diagnosis of neurodegenerative diseases, and in particular PD, for now primarily to understand the disease better,” the authors wrote. “However, in the future, once we have preventive therapy, it will become critical to find patients in the earliest stages of disease, so that we can prevent the disease from developing and affecting quality of life.”
Reference: http://dx.doi.org/10.3233/JPD-181457
SOURCE: IOS Press
“Brilliant work of many in different scientific fields has paved the way for the concept of prodromal PD -- that is, a phase of years to decades in which non-motor and subtle motor symptoms may indicate spreading PD pathology, but do not meet the threshold for diagnosis according to the classic motor-based clinical criteria,” wrote Daniela Berg, MD, Christian-Albrechts-University of Kiel, Kiel, Germany, and colleagues.
The authors define the main anchors of the concept of the prodromal phase as the broadly accepted fact that the neurodegenerative process in PD spreads slowly, possibly starting in the gut or olfactory system and finally encompassing much of the nervous system.
Increasing knowledge of risk factors and clinical symptoms that precede the typical motor manifestations by years to decades and can be correlated to imaging and histopathological findings
The authors have constructed a mathematical model that makes it possible to calculate an individual’s personal risk of being in the prodromal phase of PD. However, there are several limitations to this model, such as the time taken to conversion to PD, age, sex factors, and subtypes with undetectable prodromal stages.
“The prodromal PD criteria are meant to be research criteria and constitute a first step in what should be a continually-updated process,” the authors wrote.
Biomarkers and wearable technology such as mobile phones are expected to play a role in greater accuracy of diagnosis in the prodromal phase. The goal of biomarker research, as well as quantitative motor assessment, is to use new data arising from objective measurements to enable earlier detection of the neurodegenerative process and possibly motor symptoms. It would also facilitate the development of neuroprotective trials in early stages.
Some key questions that the authors hope to see resolved are: When is the starting point of PD? What will define the disease? Will it still be motor symptoms (possibly typical subtle ones), or will it be biomarker evidence of nigrostriatal system neurodegeneration without motor symptoms? Will it be a certain combination of non-motor signs? Or will it be based upon non-clinical biomarkers, similar to changes in Alzheimer’s disease?
By 2040, the authors hope that prodromal criteria will be incorporated into active neuroprotective treatment programs, allowing a program of population-based screening followed by early treatment and ultimately the prevention of clinical PD from ever becoming manifest.
“Our review highlights the importance of making an earlier diagnosis of neurodegenerative diseases, and in particular PD, for now primarily to understand the disease better,” the authors wrote. “However, in the future, once we have preventive therapy, it will become critical to find patients in the earliest stages of disease, so that we can prevent the disease from developing and affecting quality of life.”
Reference: http://dx.doi.org/10.3233/JPD-181457
SOURCE: IOS Press
user_24B870668 replied on
A
very clear cut clinical syndrome, REM Behavior Disorder (RBD) is a very
good indicator that typical Parkinson's Disease or it's variants will
develop at some future time and can begin a decade or more before the
first classic PD symptoms and signs. In RBD patients act out what are
usually violent or physically active dreams despite being sound asleep,
typically resulting in minor (abrasions, bruises) to serious (fractures,
head trauma) injuries to the patient or bedpartner and/or property
damage. While it occurs mostly in male patients, virtually all patients
will eventually develop PD. Perhaps the researchers should focus their
studies on RBD since it is an excellent and specific early symptom of PD
that is easily diagnosed by history. Fortunately for patients, it is
almost always quite manageable with clonazepam (and no other drug) in
low to moderate doses at bedtime.
No comments:
Post a Comment